|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | TEVA Pharmaceutical Industries Ltd (Israel), a manufacturer of generic and active pharmaceutical ingredients. |
|---|---|
| Transferring Party | IVAX Corporation, a provider of branded and generic pharmaceuticals and veterinary products. |
| Sector | Biopharmaceuticals |
| Date | July 25, 2005 |
| Analysis Creates largest generic drug manufacturer and adds branded products (for cancer, asthma and multiple sclerosis), as well as generics an deeper drug development pipeline, to Teva's portfolio. It is expected that Ivax's sales will reach $2.7 billion in 2006. The combined company will offer a wide range of pharmaceuticals and it is expected to generate sales exceeding $7 billion a year. The Deal value is $7.4 billion. More than $150 million in cost savings anticipated. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |